MGMT promoter methylation is associated with temozolomide response and prolonged progression-free survival in disseminated cutaneous melanoma

International Journal of Cancer

Volumn 136, Issue 12, 2015, Pages 2844-2853

  Tuominen, Rainer ^a   Jewell, Rosalyn ^b   Van Den Oord, Joost J ^c   Wolter, Pascal ^c   Stierner, Ulrika ^d   Lindholm, Christer ^e   Hertzman Johansson, Carolina ^a   Lindén, Diana ^a   Johansson, Hemming ^a   Frostvik Stolt, Marianne ^a   Walker, Christy ^b   Snowden, Helen ^b   Newton Bishop, Julia ^b   Hansson, Johan ^a   Egyházi Brage, Suzanne ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e RYHOV COUNTY HOSPITAL   (Sweden)

Author keywords

alkylating agents; melanoma; MGMT; temozolomide; treatment outcome

Indexed keywords

DACARBAZINE; MESSENGER RNA; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; CUTANEOUS MELANOMA; DNA METHYLATION; EPIGENETICS; FEMALE; FOLLOW UP; GENE EXPRESSION REGULATION; GENE SILENCING; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MGMT GENE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION; TREATMENT RESPONSE; TUMOR BIOPSY; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DISEASE FREE SURVIVAL; GENETICS; MELANOMA; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PROCEDURES; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; DACARBAZINE; DISEASE-FREE SURVIVAL; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MELANOMA; MIDDLE AGED; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; PROMOTER REGIONS, GENETIC; PROPORTIONAL HAZARDS MODELS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84927537650     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29332     Document Type: Article

References (36)

1. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-16.
2. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012; 367: 1694-703.
3. Menzies AM, Long GV,. Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond. Eur J Cancer 2013; 49: 3229-41.
4. Christmann M, Verbeek B, Roos WP, et al. O(6)-Methylguanine-DNA methyltransferase (MGMT) in normal tissues and tumors: enzyme activity, promoter methylation and immunohistochemistry. Biochim Biophys Acta 2011; 1816: 179-90.
5. Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000; 18: 158-66.
6. Serrone L, Zeuli M, Sega FM, et al. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer Res 2000; 19: 21-34.
7. Sun W, Schuchter LM,. Metastatic melanoma. Curr Treat Opt Oncol 2001; 2: 193-202.
8. Kim C, Lee CW, Kovacic L, et al. Long-term survival in patients with metastatic melanoma treated with DTIC or temozolomide. Oncologist 2010; 15: 765-71.
9. Paz MF, Yaya-Tur R, Rojas-Marcos I, et al. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res 2004; 10: 4933-8.
10. Brandes AA, Tosoni A, Franceschi E, et al. Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation With MGMT promoter methylation status. J Clin Oncol 2009; 27: 1275-9.
11. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352: 997-1003.
12. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10: 459-66.
13. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000; 343: 1350-4.
14. Felsberg J, Thon N, Eigenbrod S, et al. Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas. Int J Cancer 2011; 129: 659-70.
15. Hassel JC, Sucker A, Edler L, et al. MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome. Br J Cancer 2010; 103: 820-6.
16. Sasaki M, Anast J, Bassett W, et al. Bisulfite conversion-specific and methylation-specific PCR: a sensitive technique for accurate evaluation of CpG methylation. Biochem Biophys Res Commun 2003; 309: 305-9.
17. Melin J, Quake SR,. Microfluidic large-scale integration: the evolution of design rules for biological automation. Annu Rev Biophys Biomol Struct 2007; 36: 213-31.
18. Jang JS, Simon VA, Feddersen RM, et al. Quantitative miRNA expression analysis using fluidigm microfluidics dynamic arrays. BMC Genomics 2011; 12: 144.
19. Spurgeon SL, Jones RC, Ramakrishnan R,. High throughput gene expression measurement with real time PCR in a microfluidic dynamic array. PLoS One 2008; 3: e1662.
20. Gilbert MR, Wang M, Aldape KD, et al. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol 2013; 31: 4085-91.
21. Busch C, Geisler J, Lillehaug JR, et al. MGMT expression levels predict disease stabilisation, progression-free and overall survival in patients with advanced melanomas treated with DTIC. Eur J Cancer 2010; 46: 2127-33.
22. Cesinaro AM, Sartori G, Migaldi M, et al. Prognostic significance of MGMT gene promoter methylation in differently treated metastatic melanomas. Pathology 2012; 44: 313-7.
23. Schraml P, von Teichman A, Mihic-Probst D, et al. Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07. Oncol Rep 2012; 28: 654-8.
24. Alkam Y, Mitomi H, Nakai K, et al. Protein expression and methylation of DNA repair genes hMLH1, hMSH2, MGMT and BRCA1 and their correlation with clinicopathological parameters and prognosis in basal-like breast cancer. Histopathology 2013; 63: 713-25.
25. Pietrantonio F, Perrone F, de Braud F, et al. Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation. Ann Oncol 2014; 25: 404-8.
26. Wierzbicka-Hainaut E, Sassolas B, Mourey L, et al. Temozolomide and cisplatin combination in naive patients with metastatic cutaneous melanoma: results of a phase II multicenter trial. Melanoma Res 2010; 20: 141-6.
27. Bafaloukos D, Tsoutsos D, Kalofonos H, et al. Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: a randomized phase II study of the Hellenic Cooperative Oncology Group. Ann Oncol 2005; 16: 950-7.
28. Masucci GV, Mansson-Brahme E, Ragnarsson-Olding B, et al. Alternating chemo-immunotherapy with temozolomide and low-dose interleukin-2 in patients with metastatic melanoma. Melanoma Res 2006; 16: 357-63.
29. Malley DS, Hamoudi RA, Kocialkowski S, et al. A distinct region of the MGMT CpG island critical for transcriptional regulation is preferentially methylated in glioblastoma cells and xenografts. Acta Neuropathol 2011; 121: 651-61.
30. Cankovic M, Nikiforova MN, Snuderl M, et al. The role of MGMT testing in clinical practice: a report of the association for molecular pathology. J Mol Diagn 2013; 15: 539-55.
31. Ranson M, Hersey P, Thompson D, et al. Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma. J Clin Oncol 2007; 25: 2540-5.
32. Briegert M, Kaina B,. Human monocytes, but not dendritic cells derived from them, are defective in base excision repair and hypersensitive to methylating agents. Cancer Res 2007; 67: 26-31.
33. Weiler M, Blaes J, Pusch S, et al. mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy. Proc Natl Acad Sci USA 2014; 111: 409-14.
34. Pfaffl MW,. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29: e45.
35. Livak KJ, Schmittgen TD,. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 2001; 25: 402-8.
36. Vandesompele J, De Preter K, Pattyn F, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002; 3: RESEARCH0034.